Company Search:
Advanced Search
Sponsored Links
Mesoblast Ltd - ADR Company Snapshot
Mesoblast Ltd operates within the Commercial physical research sector. In addition to historical fundamental analyses, the complete report available to purchase compares Mesoblast Ltd with three other companies in this sector in the United States: Clinuvel Pharmaceuticals Limited (2019 sales of $22.59 million of which 100% was Biotechnology), Kalvista Pharmaceuticals Inc ($16.13 million of which 100% was Pharmaceuticals), and Pharmaxis Ltd ($8.97 million of which 48% was New Drug Development).

Sales Analysis. During the year ended June of 2019, sales at Mesoblast Ltd were $16.72 million. This is a decrease of 3.6% versus 2018, when the company's sales were $17.34 million.
  Stock Performance Chart for Mesoblast Ltd - ADR
  Stock Data: Recent Stock Performance:
  Current Price (2/21/2020): 9.24
(Figures in U.S. Dollars)
1 Week -2.8%   13 Weeks -13.1%  
4 Weeks 53.2%   52 Weeks 108.1%  
Mesoblast Ltd - ADR Key Data:
  Ticker: MESO Country: United States
  Exchanges: OTC Major Industry: Commercial Services & Supplies
    Sub Industry: Commercial Physical Research
  2019 Sales 16,722,013
(Year Ending Jan 2020).
Employees: 83
  Currency: U.S. Dollars Market Cap: 916,015,594
  Fiscal Yr Ends: June Shares Outstanding: 99,135,887
  Share Type: Ordinary Closely Held Shares: 22,379,719
Feedback | Terms and Conditions | Privacy Policy | Site Index
CorporateInformation® website and selected data Copyright © 2000 - by The Winthrop Corporation. All Rights Reserved. Except for quotations by established news media, no pages on this site may be reproduced, stored in a retrieval system, or transmitted for commercial purposes, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without prior written permission. Information is believed reliable, but accuracy, completeness and opinions are not guaranteed.